UH Cancer Center backs bills to boost cigarette tax 2 cents
GEORGE F. LEE / GLEE @STARADVERTISER.COM The University of Hawaii Cancer Center in Kakaako as seen Thursday.
GEORGE F. LEE / GLEE @STARADVERTISER.COM The University of Hawaii Cancer Center in Kakaako as seen Thursday.
The University of Hawaii Cancer Center would receive a welcomed funding boost if the Legislature increases the state's cigarette tax by another 2 cents, while a separate Senate bill would have forced the center to merge with the UH medical school, which UH previously said would jeopardize the center's accreditation.
UH officials and health and cancer organizations support Senate Bill 1528 and the latest version of House Bill 441, which would increase the cigarette—or 'little cigar '—tax to 18 cents from 16 cents.
The additional tax would be dedicated to the Hawai 'i Cancer Research special fund while simultaneously making it more expensive to buy cigarettes across the islands.
The latest version of HB 441 has been scheduled for a House Education Committee this afternoon at the Manoa campus with the UH Board of Regents.
SB 1528 has been referred to different Senate committees but has yet to be scheduled for hearings.
UH officials Thursday continued to push back against the latest effort by state Sen. Donna Kim—who chairs the Senate Higher Education Committee—to merge the Cancer Center with UH's John A. Burns School of Medicine and have the center's director report directly to the medical school dean.
Don 't miss out on what 's happening !
Stay in touch with breaking news, as it happens, conveniently in your email inbox. It 's FREE !
Email 28141 Sign Up By clicking to sign up, you agree to Star-Advertiser 's and Google 's and. This form is protected by reCAPTCHA.
A similar bill Kim introduced in 2020 was opposed by then-UH President David Lassner.
In his testimony at the time, Lassner said Kim's bill usurped the authority of the UH Board of Regents while placing the UH Cancer Center's accreditation from the National Cancer Institute at risk.
Kim's 2020 bill 'would replace the judgment and decision of the Board of Regents, which established the Cancer Center in 1981, ' Lassner wrote in testimony at the time, 'without regard for the potentially devastating impacts of such a change.'
At the time, the Cancer Center had been designated as one of only 71 NCI-designated cancer centers in the nation. There are now 72.
Earlier in 2020, Lassner said the center was visited by a committee composed of cancer center directors from across the county who made their annual visit to the UH Cancer Center to ensure it was complying with NCI guidelines.
He quoted the committee for praising the center's 'free-standing center with defined authority ' as 'vital ' for its success and continued NCI designation.
Lassner also quoted the chair of the evaluation committee as saying that 'most institutions ' were interpreting NCI guidelines 'as meaning the cancer center director should have the authority equivalent to that of a dean.'
Kim's current proposal—SB 1204—provides no justification or reasoning for folding the Cancer Center into the medical school and making the center's director report to the JABSOM dean.
During a Senate Higher Education Committee Thursday on SB 1204, new UH President Wendy Hensel told the committee that UH Manoa Provost Michael Bruno was working on developing a recommendation over whether to merge the Cancer Center into JABSOM.
Bruno told Kim that the possibility of a merger could 'take advantage of efficiencies.'
And UH officials acknowledged that half of the 72 NCI-accredited cancer centers around the country operate within their medical schools.
Currently, Hensel said, the Cancer Center sits among 'the top 4 % in the country ' compared with all other cancer centers.
Hensel asked Kim to 'respectfully … withdraw the bill ' to give UH time to research the issue and make a recommendation on how to proceed for the 2026 legislative session.
Kim, clearly exasperated, said she has been asking for years for a plan and recommendation from UH over what to do about the Cancer Center.
But Kim agreed to defer her bill—in yet another sign of the honeymoon period Hensel continues to enjoy with key senators after years of them expressing unhappiness and open frustration toward Lassner and his top administrators.
'Your frustration is certainly justified, ' Hensel told Kim. 'We will get it done.'
Before Thursday's Higher Education hearing, Bruno and Cancer Center Director Naoto Ueno wrote in testimony supporting increasing the cigarette tax that Cancer Center funding has fallen as statewide smoking cessation efforts have succeeded.
More than 70, 000 people in Hawaii 'are living with cancer and praying for a cure, and each year 2, 300 Hawai 'i residents die of this terrible disease, ' they wrote.
Cigarette tax revenue helped build the Cancer Center and its ongoing anti-cancer efforts.
'However, due to the success of smoking cessation efforts, this revenue has declined, indicating both progress in public health and a concerning decrease in resources for the initiatives that have fueled this advancement, ' Nueto and Bruno wrote.
'Now providing less than half the funding compared with that of 2009, this source of revenue is no longer able to support its original intent to provide a top-notch facility, and to invest in the most promising cancer research, clinical care and community outreach.'
Opposition includes testimony from Tina Yamaki, president of the Retail Merchants of Hawaii.
She wrote that increasing the tax would disproportionately hurt sales for small businesses, 'potentially leading to job losses and closures in an already fragile economic climate. We would also see more people purchasing these products on military bases or having friends and family purchasing it for them.'
'The higher price of these types of goods would only make it more attractive to shoplift, ' Yamaki wrote.
Support for an increase in the cigarette tax to help the Cancer Center has come from Hawai 'i Pacific Health, The Queen's Health Systems, the Hawaii Medical Association, the Hawaii Medical Service Association and the American Cancer Society Cancer Action Network.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
UH program that helps struggling ʻohana on federal chopping block
HONOLULU (KHON2) — A University of Hawaiʻi at Mānoa program aimed at helping struggling ʻohana and kūpuna is on the federal chopping block as the U.S. Congress looks at cutting its funding. UH's SNAP-Ed program, which is run by the College of Tropical Agriculture and Human Resilience, receives federal funding for its operations, which includes teaching ʻohana how to prepare healthy and affordable meals. Early morning vehicle collisions hospitalize two 'Our college has been working with local families and kūpuna through SNAP-Ed for more than 20 years,' SNAP-Ed Program Director Jean Butel said. 'Our SNAP-Ed program has become a trusted community partner that helps about 15,000 community members across Hawaiʻi every year. We meet people where they are: public schools, farmer's markets, senior care facilities and other community gathering places.' In addition to teaching people how to make healthy meals, the program also helps families budget for their groceries and even shows them how to grow their own produce. According to UH, 91% of participants in the program improved their diet, 83% learned how to budget better and 40% said they could afford more food for their ʻ for the SNAP-Ed program has been completely cut from the budget, which is currently being debated by the federal legislature, which puts local families at risk of losing a vital resource, UH said. 'We are grateful that Hawaiʻi's Congressional delegation fully supports SNAP-Ed,' said college Dean Parwinder Grewal. 'With our geographic isolation, high cost of living and ongoing food insecurity, full funding is essential for Congress to continue supporting Hawaiʻi's SNAP-Ed families and kūpuna.' Should the federal government approve of the cuts, the program will expire on Sept. 30, potentially further hurting already struggling locals. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 days ago
- Yahoo
Successful drone attack on Russia exposes US vulnerabilities: Lawmakers
WASHINGTON (NewsNation) — Ukraine's recent crippling attack on Russia's bomber fleet raises new concerns that the U.S. is unprepared for a drone attack on American soil. Lawmakers from both parties who have spoken with NewsNation agree that American airspace is vulnerable, and the highly-strategized Ukrainian drone shows just how much damage a relatively inexpensive drone can do to a multimillion-dollar aircraft, as was the case in Russia. The targets were Russian warplanes, including strategic bombers and command-and-control aircraft, worth hundreds of millions of dollars. The weapons were Ukrainian drones, each costing under $1,000 and launched from wooden containers carried on trucks. 'Hard to believe' drone attacks without US knowledge: Mark Halperin 'Operation Spiderweb,' which Ukraine said destroyed or damaged over 40 aircraft parked near air bases across Russia on Sunday, wasn't just a blow to the Kremlin's prestige. It was also a wake-up call for the West to bolster its air defense systems against such hybrid tactics. How deeply the attack will impact Russian military operations is unclear. Although officials in Kyiv estimated it caused $7 billion in damage. Army Secretary Daniel Driscoll and Federal Aviation Administration Chief Chris Rocheleau were recently grilled during Capitol Hill testimony on the safety of American airspace. NewsNation spoke exclusively with U.S. Sen. Andy Kim, D-N.J., who says there are problems with the airspace when it comes to detecting drones or incursions. He says, at this point, the U.S. still cannot do that in an efficient way to prevent what could be a serious threat. Chinese-owned US farmland raises concerns of foreign drone attacks Kim pointed to recent mysterious drone sightings over the Garden State, sightings that Transportation Secretary Sean Duffy still cannot explain. 'Regardless of what was flying up in the skies in New Jersey, the fact that our military bases didn't know what was going on, nor did they have a clarity of how they would have responded if it was something dangerous or nefarious, shows that we're just not at the level of readiness to be able to take this on,' said Kim. 'And this isn't just about our military bases. It's about critical infrastructure, water treatment plants, power plants.' Back in January, newly sworn-in President Donald Trump said all of what were seen over New Jersey were FAA-authorized aircraft, a break from what Duffy told NewsNation. Senators who spoke with NewsNation said that in the not-so-distant past, the FAA and the Department of Defense were not necessarily communicating with each other. Sources tell NewsNation the two agencies are now sharing more information when it comes to drone sightings. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 days ago
- Yahoo
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL. In a recent Q&A hosted by Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, a patient advocacy group, Dr. Kim shared her gratitude to clinical trial participants and emphasized the urgent need for safer, more effective therapies for CTCL. The conversation underscored the progress being made with HyBryte™, Soligenix's novel, non-mutagenic photodynamic therapy. 'We need new therapies and access to therapies [for patients],' said Dr. Kim, noting that CTCL is a chronic disease which means that therapies with possible side effects, such as the development of contact dermatitis, sun damage or skin cancer from phototherapy, can become a real issue for patients over time. 'There hasn't been an FDA-approved, new skin-directed therapy for over 10 years, so we really need new ones that are safe and hopefully safer [than the ones currently in use].' Clinical results from ongoing studies have been promising, with Dr. Kim noting that participants have experienced positive outcomes and that the therapy has been well tolerated, with no dropouts due to serious adverse events. "HyBryte™ has a unique mechanism of action, so it doesn't damage DNA, unlike phototherapy, so theoretically it's less mutagenic and there's less risk of skin cancer. It's not systemically absorbed, based on prior studies, and seems to be quite well tolerated in terms of its effects on the local skin area,' added Dr. Kim. As a professor of dermatology at the Hospital of the University of Pennsylvania and Director of the Penn Cutaneous Lymphoma Program, Dr. Kim is keen to continue her research into CTCL with colleagues and patients alike. 'There aren't that many clinical trials going on for early-stage disease,' Dr. Kim stated, adding she is very excited for what lies ahead now that open enrollment in HyBryte™ clinical trials is available. 'Hopefully we can get this over the finish line. We can't thank patients enough; it's so critical for getting new therapies approved.' To watch Dr. Kim's interview and learn more about the real-world clinical study of the treatment of Mycosis Fungoides with Synthetic Hypericin and Visible Light, please visit: About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer (SGX942), and in Behçet's Disease (SGX945). Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA). For further information regarding Soligenix, Inc., please visit the Company's website at and follow us on LinkedIn and Twitter at @Soligenix_Inc. This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma or any other studies (including the open-label, investigator-initiated study), there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events. Corporate Communications IBN Austin, Texas 512.354.7000 Office Editor@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
